Furthermore, we demonstrate that BCL2 inhibitors are synthetically lethal in breast cancer cells when combined with the glycolysis inhibitor 2DG, a finding that we also observed when cells were grown in 3D spheroids. Here, BCL2 is linked to breast carcinoma.